| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Sarafloxacin is another new animal-specific drug after enrofloxacin. It was developed and marketed by Abbott in the United States. The antibacterial activity of this product is stronger than that of difloxacin, norfloxacin, ofloxacin-amika The antibacterial activity of namycin and tobramycin against anaerobic bacteria is comparable to that of ciprofloxacin.
This product is broad-spectrum antibacterial, and is relatively effective against Escherichia coli, Salmonella, Pasteurella multocida, Proteus, Haemophilus, Pasteurella hemolytica, Staphylococcus (including penicillin-resistant beads), Streptococcus, Mycoplasma, etc. Strong inhibitory effect, the MIC90 (ug/ml) of the first three were 0.06, 0.06 and 0.015, respectively, and also had more antibacterial effects. Pharmacokinetics: This product is rapidly absorbed after oral administration and injection. Wide distribution in the body, large apparent volume of distribution, high bioavailability orally, elimination half-life Indications: antibacterial drugs. It has a strong killing effect on Gram-positive bacteria, negative bacteria and mycoplasma.
|
|
Foreign name :sarafloxacin hydrochloride/sarafloxacin Molecular formula and molecule C20H18ClF2N3O3 Melting point≥300ºC Properties; Off-white to pale yellow crystalline powder CAS No. 91296-87-6 Molecular formula: C20H18ClF2N3O3 Molecular weight: 421.83 |
){kind=link}